Aun R. Shah

Aun R. Shah

Auto-generated profile, based on publicly available information

Aun R. Shah

Division of Gastroenterology and Hepatology, Creighton University School of Medicine, Omaha, Nebraska, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
ASAun R. Shah
Aun R. Shah
SUShifa Umar
Shifa Umar
MBMohammad Bilal
Mohammad Bilal
AKAhmad Khan
Ahmad Khan
RARubab Ali
Rubab Ali
MAMarwan S. Abougergi
Marwan S. Abougergi

19 September 2024 in Gastro Hep Advances
Verified
Journal Article
Open access
ASAun R. Shah
Aun R. Shah
NANurlan Aliyev
Nurlan Aliyev
ZKZarak H. Khan
Zarak H. Khan
RARubab Ali
Rubab Ali
MBMohammad Bilal
Mohammad Bilal

6 January 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CMClive J. Miranda
Clive J. Miranda
ASAun R. Shah
Aun R. Shah
An abstract is unavailable. This article is available as a PDF only.

28 August 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ECEduardo A. Canto
Eduardo A. Canto
ARAmar K. Rai
Amar K. Rai
SLStephen J. Lostetter
Stephen J. Lostetter
AAAditya V. Avula
Aditya V. Avula
TRThomas Round
Thomas Round
SMSteven F. Moss
Steven F. Moss
INTRODUCTION: Current guidelines suggest swallowable capsule-sponge devices with biomarkers can be used as alternatives to endoscopy for detecting Barrett's Esophagus (BE) in at-risk patients. We analyzed the screening performance of capsule-sponge with trefoil-factor-3 (TFF3) in patients with symptomatic acid reflux and assessed test performance across individual risk factors. METHODS: The study protocol was registered in Prospective Register of Systematic Reviews (PROSPERO) (CRD420250652091). Eligible studies reported results for both capsule-sponge-TFF3 and endoscopic assessment in adults with reflux symptoms and no history of BE. A systematic search was conducted through August 29, 2025. Two reviewers independently screened and extracted data using COllaboration + eVIDENCE (COVIDENCE). Risk of bias was assessed by QUality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Sensitivity and specificity were estimated in SAS v9.4 using bivariate mixed models allowing estimation of likelihood ratios, diagnostic odds ratios, and predictive values; meta-regression models were estimated for individual risk factors, acid suppressant use and BE prevalence. RESULTS: We identified 6 studies involving 1,454 participants in our meta-analysis. Pooled sensitivity for BE was 0.87 (95% CI: 0.80–0.94), specificity was 0.88 (95% CI: 0.80–0.95), negative predictive value at 20% prevalence was 0.96 (95% CI: 0.95–0.98), and the diagnostic odds ratio was 47.82 (95% CI: 44.99–50.83). Smoking and acid suppressant use were associated with increased specificity. DISCUSSION: Overall, our findings show that capsule-sponge-TFF3 is an effective minimally invasive screening tool for patients at risk of BE. Increased specificity in smokers may help reduce unnecessary endoscopies in this higher-risk group.